Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for ...

Medicare and Medicaid recipients can be reimbursed ... As an obesity treatment, Wegovy, made by Novo Nordisk, comes with a slightly higher dose for treating obesity than doses for diabetes ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

April 14, 2025 Novo Nordisk warns consumers about counterfeit ... in the government's final reimbursement rates for 2026 Medicare Advantage health plans run by private insurers, more than double ...